key: cord-0788996-79xxalsl authors: Chen, Jen-Ting; Ostermann, Marlies title: Review of Anti-inflammatory and Anti-viral therapeutics for hospitalized patients infected with SARS-CoV-2 date: 2022-02-14 journal: Crit Care Clin DOI: 10.1016/j.ccc.2022.02.002 sha: 59490ff12e52e2a7c6b86d9fd2862a89c0b445b7 doc_id: 788996 cord_uid: 79xxalsl SARS-CoV-2 infection leads to dysregulation of immune pathways. Therapies focusing on suppressing cytokine activity have some success. Current evidence supports the use of dexamethasone in hospitalized patients requiring oxygen to decrease mortality. IL-6 inhibitors like tocilizumab and sarilumab are also beneficial in hypoxemic patients, if used early. JAK inhibition in combination with glucocorticoids is emerging as a potential therapeutic option for patients with moderate to severe symptoms. Data on the role of anakinra, hyperimmune immunoglobulin/convalescent plasma, or plasma purification is limited. SARS-CoV-2 infection leads to dysregulation of immune pathways. Therapies focusing on suppressing cytokine activity have some success. Current evidence supports the use of dexamethasone in hospitalized patients requiring oxygen to decrease mortality. IL-6 inhibitors like tocilizumab and sarilumab are also beneficial in hypoxemic patients, if used early. JAK inhibition in combination with glucocorticoids is emerging as a potential therapeutic option for patients with moderate to severe symptoms. Data on the role of anakinra, hyperimmune immunoglobulin/convalescent plasma, or plasma purification is limited. J o u r n a l P r e -p r o o f Introduction: Sepsis is defined as a dysregulated host response to infection with an imbalance of proand anti-inflammatory cytokines 1 . As the first line of defence to infection, the innate immune system is activated and produces pro-inflammatory cytokines leading to indiscriminate destruction of foreign or infected cells. Pro-inflammatory mediators then further trigger downstream physiologic processes leading to activation of coagulation pathways, endothelial dilatation and increased permeability, complement activation, recruitment of adaptive immunity, and ultimately production of anti-inflammatory cytokines to balance the pro-inflammatory state 2 . When left unchecked, hyperinflammation may occur, resulting in tissue damage, acute respiratory distress syndrome (ARDS), vasodilatory shock, disseminated intravascular coagulopathy (DIC), intravascular formation of microthrombi and death. This unchecked hyperinflammatory state is sometimes referred to as "cytokine storm" 3 . During the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic in 2020, some hospitalized patients with severe SARS-CoV-2 infection were reported to have lymphopenia and thrombocytopenia, as well as elevated acute phase reactants such as ferritin and C-reactive protein, and raised liver enzymes and d-dimer 4 . Not surprisingly, the derangement of these biomarkers was directly associated with worse outcomes 5 . The inflammatory profile of patients with moderate to severe SARS-CoV-2 infection is similar to that of patients with acute respiratory distress syndrome (ARDS) and sepsis [5] [6] [7] . In a prospective study, Wilson et al compared the cytokine profiles of patients with Coronavirus disease 2019 (COVID-19) with historical patients suffering from ARDS or Sepsis 6 . They found no difference in 6 major cytokines [Interleukins (IL)-1, IL-1RA, IL-6, IL-8, IL-18, and tumor necrosis factor (TNF)-]. Elevated cytokine concentrations are associated with increased severity of SARS-CoV-2 infections 8 . The pathogenesis of SARS-CoV-2 infection includes various phases. J o u r n a l P r e -p r o o f ( Figure 1 ). In the early phase, the virus enters the cells after binding of the spike unit to the angiotensin converting enzyme 2 (ACE2) receptor 9 . The host cell protease facilitates viral fusion and cell entry following which viral RNA processing occurs. The viral N-protein inhibits interferon production which decreases recruitment of innate immunity cells and viral clearance [9] [10] [11] . As viral replication continues, host cell death ensues resulting in the release of excessive intracellular material, including cytokines and chemokines. Symptomatically, the host experiences hypoxemia and can develop ARDS and additional organs dysfunction. A myriad of cytokines may be involved in this process 12 . Clinical trials have demonstrated improved outcomes in patients with severe or critical COVID-19 with immunomodulatory therapies. In this chapter, we will review the current level of evidence. Glucocorticoids are fat soluble hormones that bind to transmembrane receptors as well as intracellular receptors. In the setting of stress, glucocorticoids are released by the adrenal glands and bind to the glucocorticoid receptor, a transcription factor in target cells. Glucocorticoid receptor binding has strong anti-inflammatory downstream effects ranging from transcriptional action, protein modification, and direct cell type specific directives (Table 1) 13 . A variety of glucocorticoids including dexamethasone, prednisone, hydrocortisone, and methylprednisolone have been trialled; the largest study, conducted by the RECOVERY collaborative group, examined dexamethasone [14] [15] [16] [17] . Therapy with dexamethasone has become standard of care for SARS-CoV-2 patients requiring oxygen therapy. weeks after initial hospital admission 22 . It is recommended to involve multidisciplinary medical teams to determine the best course of action in this patient population 22, 23 . Glucocorticoid selection: Hydrocortisone is the equivalent of cortisol when used as a drug; other formulations are compared with hydrocortisone 13 , in terms of potency and duration of action. Dexamethasone is the most potent anti-inflammatory and longest acting corticosteroid followed by methylprednisolone, prednisone, and hydrocortisone (least potent). They have all been used to treat oxygen-requiring patients with SARS-CoV-2 infection. Dexamethasone is known to suppress IL-1 signalling pathways, specifically c-Jun Nterminal kinase (JNK)-p38, leading to suppression of macrophage release of downstream cytokines such as IL-6, IL-8 and TNF 24 . Similarly, hydrocortisone use in patients with severe sepsis has been shown to significantly decrease IL-1, IFN-, TNF-, and IL-6 levels 25 . Methylprednisolone has been reported to have some benefit in acute lung injury 26 . Dexamethasone, hydrocortisone, and methylprednisolone have been used in ARDS clinical trials. In DEXA-ARDS study, Villar et al. investigated the role of dexamethasone (20mg for 5 days followed by 10mg for 5 more days) 27 . Hospital mortality was reduced by 12.5% (95% CI -22.9 to -1.7) with an increase in ventilator free days of 4.8 (95% CI 2.57 to 7.03) in those treated with dexamethasone. The COVID-19 Dexamethasone (CoDex) RCT has been completed in Brazil 28 . It included mechanically ventilated patients with moderate to severe ARDS who were randomized to receive 20mg of dexamethasone for 5 days followed by 10mg of dexamethasone for 5 additional days. There was not significant difference in all-cause mortality between the two groups, in contrast to the original DEXA-ARDS results 27, 28 . Furthermore, both the Community acquired pneumonia-COVID (CAPE-COVID) trial and the randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia (REMAP-CAP) trial randomized patients to 200mg of daily hydrocortisone J o u r n a l P r e -p r o o f (equivalent of dexamethasone 7mg) or placebo 15 . There was no significant mortality benefit or difference in organ support free days 15, 29 . Methylprednisone infusion also did not lead to significant mortality benefits 16 . None of the studies showed differences in serious adverse events between the glucocorticoid and placebo arms. The RECOVERY trial, compared Dexamethasone 6 mg daily for 10 days versus standard care and demonstrated a significantly lower mortality 14 In conclusion, current evidence supports the use of dexamethasone 6 mg daily for 10 days in hospitalized SARS-CoV-2 patients requiring oxygen therapy (Table 2) . Steroid should be avoided in asymptomatic or mild disease. Increasing the dose to 12mg can be considered. The actions of dexamethasone are likely to be more systemic rather than intrapulmonary. Indeed, a follow up report of the CORIMUNO-TOCU-1 study showed that a CRP cut-off of 150mg/L was associated with reduced 90 day mortality (OR 0.18, 95% CI 0.04-0.89) 45 . Furthermore, patients with critical disease requiring mechanical ventilation or extracorporeal membrane oxygenation (ECMO) were least likely to benefit in contrast to patients treated with supplemental oxygen or NIV 35 . In conclusion, early use of IL-6 antagonists is beneficial for hypoxemic patients with COVID-19 requiring oxygen ( Table 2 ). The use of IL-6 receptor inhibitor therapy in patients on mechanical ventilation is likely too late and unlikely to improve outcomes. IL-6 antagonists should be used in conjunction with corticosteroids. CRP levels may identify individuals with more potential to benefit. The Janus kinase-signal transducer and activator of transcription (JAK-STAT) signalling pathway mediates extracellular interleukins and interferons signal, through membrane receptor activation, and leads to T-cell proliferation and maturation 46 . Cytokine receptor binding phosphorylates JAK and allows docking for cytoplasmic STATs ( Figure 1 ) 12 . JAK phosphorylates STAT protein, allowing STAT to move into the nucleus. STAT regulates inflammatory and immune response, viral clearance, cell proliferation and survival, endothelial integrity, and coagulation pathways 47 . IL-6 receptor downstream activity is mediated by JAK-STAT pathway, specifically IL-6 receptor activation of STAT3 is associated with lung fibrosis and injury, thrombosis, and delayed J o u r n a l P r e -p r o o f viral clearing by blocking IFN response of STAT-1. The rationale for baricitinib was based not only on its anti-inflammatory property to inhibit JAK, but also the ability to inhibit other kinases associated with viral endocytosis 48 . In addition, the JAK-STAT pathway mediates Angiotensin II function in the cardiovascular system 31 . An observational study in SARS-CoV-2 patients showed that baricitinib significantly reduced CRP and increased T-lymphocyte count with an increase of the CD4+ to CD8+ cell ratio 49 In summary, JAK inhibition is effective in preventing SARS-CoV-2 progression and has potential to decrease mortality in patient requiring low flow oxygen but not in those with severe symptoms. JAK inhibitors should be used concomitantly with glucocorticoids (Table 2) . IL-1 is transcribed by monocytes, macrophages and dendritic cells following Toll-like receptor activation by pathogens 54 . IL-1 binding triggers protein complexes at the intracellular membrane with two further downstream pathways: activation pathway for cellular survival and inhibitory pathway for B-cell maturation 55, 56 . The use of anakinra in mild to moderate SARS-CoV-2 infection was not supported by a recent RCT 57 . 116 patients were randomized to receive anakinra versus usual care. Only a small proportion of the patients received glucocorticoids (14%). There was no difference in terms of symptom progression at day 4 and day 14 in the primary outcomes and the overall survival. In the early phase of the COVID-19 Pandemic, multiple anti-viral drugs were repurposed as potential to treat SARS-CoV-2 infection, including lopinavir-ritonivir and remdesivir 58, 59 . The viral protease inhibitor combination, lopinavir-ritonivir, is not effective in SARS-CoV-2 infection 58, 60, 61 . Remdesivir is an inhibitor of viral RNA-dependent RNA polymerase. In a large randomized controlled study including 1062 patients, remdesivir decreased time to recovery by 5 days and this overall effect was mostly driven by patients receiving oxygen 59 . In patients with severe to critical infection at time of enrolment, remdesivir did not shorten time to recovery. Ultimately, the meta-analysis by the WHO Solidarity group did not show a mortality benefit with the use of remdesivir regardless of subgroups by age or by severity of infection 60 . Furthermore, the WHO living guideline suggests against the use of remdesivir in hospitalized patients with SARS-CoV-2 infection 62 . New anti-viral drugs against SARS-CoV-2 are rapidly emerging as this review is being prepared. Molnupiravir, an oral pro-drug of ribonucleoside analog against RNA viruses, has good tolerability and potential in decrease viral load in early SARS-CoV infection 63, 64 . Further phase 3 studies are necessary to determine the efficacy. In viral infection, IVIG has been proposed to provide passive immunity to mediate antibody dependent cellular cytotoxicity and acts as decoy receptor to prevent viral binding and entry 65 J o u r n a l P r e -p r o o f Similar to the concept of using immunoglobulin binding, convalescent plasma from previously SARS-CoV-2 infected individual was initially thought to potentially confer passive immunity in currently infected individuals. In a multicentre, double blinded RCT of 334 patients with moderate SARS-CoV-2 symptoms, convalescent plasma infusion failed to improve clinical status at 30 days 67 . The RECOVERY study group tested the efficacy of convalescent plasma in 11,558 patients with majority of them requiring oxygen in the hospital (87%) 68 . There was no mortality or other clinical benefit in the treatment group. A large meta-analysis found no efficacy associated with the use of convalescent plasma and pointed out the high risk of bias in the included studies 69 . Two combinations of neutralizing antibodies: casirivimab with imdevimab (Regen-COV) and bamlanivimab with etesevimab, targeting SARS-CoV-2 surface spike protein decrease viral load compared to placebo in patients with mild to moderate symptoms 70, 71 . Used in the ambulatory settings, these monocolonal antibody cocktails prevent hospitalization 71, 72 . However, hospitalized patients treated with anti-SARS-CoV-2 antibodies did not have different symptom progression compared to standard of care 73 . RECOVERY study examined the use of casirivimab with imdevimab in hospitalized patient only and found mortality benefit in subgroup of patients who were seronegative of SARS-CoV-2 at time of randomization 74 . Limited data is available for the use of plasma exchange in patients with severe to critical SARS-CoV-2 infection. An open label study randomized patients to therapeutic plasma exchange and usual care. There was no significant mortality benefit despite sustained decrease in IL-6 levels 75 . Currently, there is no clinical evidence to support the use of these methods [76] [77] [78] . inhibitors is also beneficial in hypoxemic patients. CRP level can serve to identify patients who may benefit from IL-6 inhibitors. JAK inhibition in combination with glucocorticoids is emerging as a potential therapeutic option for patients with moderate to severe symptoms. Direct antiviral therapy is not effective in hospitalized patients with severe symptoms. Data on anakinra, hyperimmune immunoglobulin/convalescent plasma, or plasma purification is limited and inconclusive. J o u r n a l P r e -p r o o f Severe sepsis and septic shock The inflammatory response in sepsis Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet Severe COVID-19 and Sepsis: Immune Pathogenesis and Laboratory Markers. Microorganisms Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis. JCI Insight Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with COVID-19 Acute Respiratory Distress Syndrome Cytokine release syndrome in COVID-19: Innate immune, vascular, and platelet pathogenic factors differ in severity of disease and sex An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies Pathogenesis of COVID-19 from a cell biology perspective Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19 Regulatory and Mechanistic Actions of Glucocorticoids on T and Inflammatory Cells Dexamethasone in Hospitalized Patients with Covid Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial Wuelton Marcelo Monteiro PhD, and Marcus Vinícius Guimarães Lacerda MD, for the Metcovid Team. Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With Coronavirus Disease 2019 (COVID-19; Metcovid): A Randomized, Double-blind, Phase IIb, Placebo-controlled Trial Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial Persistent Post-COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment. Annals of the Post COVID-19 Organizing Pneumonia: The Right Time to Interfere. Medicina (Kaunas) MAPK phosphatases--regulating the immune response Use of corticosteroids in influenza-associated acute respiratory distress syndrome and severe pneumonia: a systemic review and meta-analysis. Scientific reports Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019. Crit Care Explor Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial IL-6/IL-6 receptor system and its role in physiological and pathological conditions Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single-Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial Effectiveness of Tocilizumab in Patients HospitalizedWith COVID-19: A Follow-up of the CORIMUNO-TOCI-1Randomized Clinical Trial The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. The Lancet Baricitinib restrains the immune dysregulation in patients with severe COVID-19 Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. The Lancet Respiratory Medicine Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis A Brief History of IL-1 and IL-1 Ra in Rheumatology The structural pathway of interleukin 1 (IL-1) initiated signaling reveals mechanisms of oncogenic mutations and SNPs in inflammation and cancer Mammalian MAP kinase signalling cascades Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. The Lancet Respiratory Medicine Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2 Molnupiravir, an Oral Antiviral Treatment for COVID-19. medRxiv Administration of intravenous immunoglobulin in the treatment of COVID-19: A review of available evidence Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. The Lancet Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial Therapeutic plasma exchange in patients with life-threatening COVID-19: a randomised controlled clinical trial Haemoperfusion should only be used for COVID-19 in the context of randomized trials Extracorporeal Blood Purification and Organ Support in the Critically Ill Patient during COVID-19 Pandemic: Expert Review and Recommendation Cytosorb filter: An adjunct for survival in the COVID-19 patient in cytokine storm? a case report. Heart Lung FIGURE LEGEND Figure 1: Schematic of potential targets for anti-inflammation and anti-viral in SARS-CoV-2 infection 12 MCP-1: monocyte chemoattractant protein-1, VEGF: vascular endothelial growth factor, NF-B : nuclear factor -B inhibitor , MAPK: mitogen-activated protein kinase, JAK: Janus kinase, STAT: signal transducer and activator of transcription  Direct and indirect binding through other transcription factors  Decrease of IL-2 expression through AP1, NFAT and NFKB  Shift from TH1 cellular immunity to TH2 humoral immunity through decrease of IL-2, IFN gamma, and STAT4